Pancreatic Cancer Research

ResearcherKeio UniversityActive in the last 2 years

Hideyuki Hayashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4974-8015; OpenAlex author ID A5073758207. Sources: OpenAlex.

Their work

Papers
14 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 14

  1. Clinical utility of comprehensive genomic profiling for advanced pancreatic cancer: insights from real-world data analysis. First author DOI 10.1007/s10147-025-02713-5↗
  2. FOLFIRINOX in Pancreatic Cancer: Risk Factors for Febrile Neutropenia and Severe Neutropenia - Nationwide Study Analysis. Co-author DOI 10.21873/anticanres.16601↗
  3. Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyac157↗
  4. A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). Co-author DOI 10.1002/onco.13838↗
  5. Endoscopic Ultrasound-Guided Sampling for Personalized Pancreatic Cancer Treatment. Co-author DOI 10.3390/diagnostics11030469↗
  6. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan. Co-author DOI 10.1016/j.pan.2020.07.006↗
  7. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX. Co-author DOI 10.1111/cas.13883↗
  8. Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Co-author DOI 10.1016/j.pan.2018.07.006↗
  9. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan. Co-author DOI 10.1097/mpa.0000000000001049↗
  10. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic … Co-author DOI 10.1097/mpa.0000000000000760↗
  11. An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2016-0194↗
  12. [A Novel Treatment Strategy for Pancreatic Cancer Based on Gene Profiles]. Co-author PMID 27899773↗
  13. Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer. Co-author DOI 10.1038/srep18425↗
  14. [Adjuvant Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer following Gemcitabine and S-1 Chemotherapy--A Case Report]. Co-author PMID 26805368↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Satoshi Kobayashi · 5 shared papers, 2018–2023 · strength 0.48
  2. Naohiro Okano · 5 shared papers, 2018–2023 · strength 0.48
  3. Masato Ozaka · 5 shared papers, 2018–2023 · strength 0.48
  4. Akiko Todaka · 5 shared papers, 2018–2023 · strength 0.48
  5. Hiroshi Nishihara · 3 shared papers, 2016–2025 · strength 0.42
  6. Kentaro Sudo · 4 shared papers, 2018–2023 · strength 0.37
  7. Keiko Kamei · 4 shared papers, 2018–2023 · strength 0.37
  8. Nobumasa Mizuno · 4 shared papers, 2018–2023 · strength 0.37
  9. Noritoshi Kobayashi · 4 shared papers, 2018–2023 · strength 0.37
  10. Takanori Kanai∥ · 2 shared papers, 2021–2025 · strength 0.34
  11. Yoshito Komatsu · 3 shared papers, 2017–2021 · strength 0.25
  12. Akira Fukutomi · 3 shared papers, 2018–2020 · strength 0.23
  13. Yasuo Hamamoto · 1 shared paper, 2025 · strength 0.22
  14. Eiichiro So · 1 shared paper, 2025 · strength 0.22
  15. Narikazu Boku · 2 shared papers, 2018–2023 · strength 0.21
  16. Hideki Ueno · 3 shared papers, 2015–2020 · strength 0.19
  17. Naoya Sakamoto · 2 shared papers, 2017–2021 · strength 0.17
  18. Kazuaki Shimada · 3 shared papers, 2015–2017 · strength 0.16
  19. Takuji Okusaka · 3 shared papers, 2015–2017 · strength 0.16
  20. Chigusa Morizane · 3 shared papers, 2015–2017 · strength 0.16
  21. Mitsuhito Sasaki · 1 shared paper, 2023 · strength 0.15
  22. Eisuke Iwasaki · 1 shared paper, 2021 · strength 0.12
  23. Hiroki Tamagawa · 1 shared paper, 2021 · strength 0.12
  24. Yoko Shimada · 2 shared papers, 2017 · strength 0.12
  25. Hideki Ueno · 2 shared papers, 2017 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.